Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Total Liabilities: 2022-2024

Historic Total Liabilities for Entrada Therapeutics (TRDA) over the last 3 years, with Dec 2024 value amounting to $97.6 million.

  • Entrada Therapeutics' Total Liabilities fell 45.38% to $72.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.2 million, marking a year-over-year decrease of 45.38%. This contributed to the annual value of $97.6 million for FY2024, which is 56.95% down from last year.
  • As of FY2024, Entrada Therapeutics' Total Liabilities stood at $97.6 million, which was down 56.95% from $226.8 million recorded in FY2023.
  • Entrada Therapeutics' 5-year Total Liabilities high stood at $226.8 million for FY2023, and its period low was $39.5 million during FY2022.
  • Its 3-year average for Total Liabilities is $121.3 million, with a median of $97.6 million in 2024.
  • In the last 5 years, Entrada Therapeutics' Total Liabilities surged by 474.23% in 2023 and then crashed by 56.95% in 2024.
  • Entrada Therapeutics' Total Liabilities (Yearly) stood at $39.5 million in 2022, then soared by 474.23% to $226.8 million in 2023, then tumbled by 56.95% to $97.6 million in 2024.